Agios PharmaceuticalsAGIO
AGIO
About: Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Employees: 386
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
15% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 67
8% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 25
2% more capital invested
Capital invested by funds: $2.61B [Q2] → $2.65B (+$44.3M) [Q3]
0% more funds holding
Funds holding: 204 [Q2] → 205 (+1) [Q3]
1.64% less ownership
Funds ownership: 106.59% [Q2] → 104.95% (-1.64%) [Q3]
15% less call options, than puts
Call options by funds: $17.8M | Put options by funds: $21.1M
33% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$57
65%
upside
Avg. target
$66
92%
upside
High target
$75
118%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Gregory Renza 31% 1-year accuracy 27 / 87 met price target | 65%upside $57 | Outperform Maintained | 10 Dec 2024 |
Scotiabank Greg Harrison 45% 1-year accuracy 13 / 29 met price target | 118%upside $75 | Sector Outperform Maintained | 9 Dec 2024 |
Financial journalist opinion
Based on 3 articles about AGIO published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
Neutral
Business Wire
2 weeks ago
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development a.
Neutral
GlobeNewsWire
3 weeks ago
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 43rd Annual J.P.
Neutral
GlobeNewsWire
1 month ago
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease
CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the European Commission has adopted a positive decision for the designation of mitapivat, an oral, small molecule PK activator, as an orphan medicinal product (OMP) for the treatment of sickle cell disease. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.
Negative
Zacks Investment Research
1 month ago
Here's Why Agios Stock Plummeted More Than 20% on Monday
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
Negative
Investors Business Daily
1 month ago
Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug
Shares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company's thalassemia treatment, mitapivat. The post Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
1 month ago
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –
Positive
Zacks Investment Research
1 month ago
4 Medical Product Stocks to Buy From a Prospective Industry
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
Positive
Zacks Investment Research
2 months ago
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
2 months ago
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on mitapivat and tebapivat (AG-946), the company's PK activators, will be featured in oral and poster presentations during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 7-10, 2024.
Charts implemented using Lightweight Charts™